Over the past six months, Otis’s stock price fell to $88.58. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 8.6%. This was partly driven ...

Recursion could be on the verge of transforming the drug development process. However, the company has yet to demonstrate the superiority of its strategy. Moreover, Recursion is going to face growing ...